Pasar al contenido principal

ESTUDIO TEORICO DE NUEVOS MECANISMOS DE FOTOSENSIBILIZACION DE ACIDOS NUCLEICOS INDEPENDIENTES DEL OXIGENO MEDIANTE COMPLEJOS DE METALES DE TRANSICION

PID2021-127554NA-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2021
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSITAT DE VALÈNCIA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

DAU Arxiu Digital de la Universitat Ramon Llull
Publicación Artículo científico (JournalArticle)

Achieving red-light anticancer photodynamic therapy under hypoxia using Ir(iii)–COUPY conjugates

  • Ortega-Forte, Enrique
  • Rovira, Anna
  • Ashoo, Pezhman
  • Izquierdo García, Eduardo
  • Hally, Cormac
  • Abad-Montero, Diego
  • Jordà-Redondo, Mireia
  • Vigueras Bautista, Gloria
  • Deyà, Alba
  • Hernández, José Luis
  • GALINO, JORGE
  • Bosch, Manel
  • Alberto, Marta Erminia
  • Francés-Monerris, Antonio
  • Nonell, Santi
  • Ruiz, Jose
  • Marchán, Vicente
Despite the potential of photodynamic therapy (PDT), this oxygen-dependent oncological treatment is greatly restricted in the clinic by the well-known hypoxic feature of solid tumors. Here we provide new insights into the development of PDT agents based on conjugates between COUPY fluorophores and cyclometalated iridium(III) complexes with the aim of overcoming this limitation. The structural modifications carried out within the metal core of Ir(III)–COUPY conjugates, based on the incorporation of trifluorobenzyl groups at the cyclometalating ligands, enabled efficient exploitation of type I PDT mechanisms while retaining operativity under long-wavelength visible light, which facilitated deeper tissue penetration compared with short wavelengths. Photobiological evaluation revealed that Ir(III)–COUPY conjugate 3c achieved potent photocytotoxicity towards cisplatin-resistant ovarian (A2780cis) and mammary (EO771) cancer cell lines, efficiently photogenerated type I and type II ROS, and photoinduced apoptotic cell death using red light irradiation (620 nm). Importantly, this Ir(III)–COUPY conjugate retained such potent photoactivity under low-oxygen environment conditions (2% O2), delivering equipotent photocytotoxicity towards normoxic and hypoxic adherent cancer cells. Compound 3c was found to be highly phototoxic against EO771 multicellular tumor spheroids and showed no signs of toxicity or adverse effects in mice, which could facilitate in vivo phototherapeutic applications. Taken together, this study demonstrates that the conjugation between COUPY dyes and rationally designed Ir(III) complexes is a strategy at the frontier of the development of new red light-activated photosensitizers capable of operating under hypoxia, showing the promise of achieving satisfactory anticancer PDT effects., info:eu-repo/semantics/publishedVersion
DAU Arxiu Digital de la Universitat Ramon Llull
Publicación Artículo científico (JournalArticle)

Ruthenium(II) Polypyridyl Complexes Containing COUBPY Ligands as Potent Photosensitizers for the Efficient Phototherapy of Hypoxic Tumors

  • Abad-Montero, Diego
  • Gandioso, Albert
  • Izquierdo García, Eduardo
  • Chumillas, Sergi
  • Rovira, Anna
  • Bosch, Manel
  • Jordà-Redondo, Mireia
  • Castaño, Davor
  • Bonelli, Joaquín
  • Novikov, Valentin
  • Deyà, Alba
  • Hernández, José Luis
  • Galino, Jorge
  • Alberto, Marta Erminia
  • Francés-Monerris, Antonio
  • Nonell, Santi
  • Gasser, Gilles
  • Marchán, Vicente
Hypoxia, a hallmark of many solid tumors, is linked to increased cancer aggressiveness, metastasis, and resistance to conventional therapies, leading to poor patient outcomes. This challenges the efficiency of photodynamic therapy (PDT), which relies on the generation of cytotoxic reactive oxygen species (ROS) through the irradiation of a photosensitizer (PS), a process partially dependent on oxygen levels. In this work, we introduce a novel family of potent PSs based on ruthenium(II) polypyridyl complexes with 2,2′-bipyridyl ligands derived from COUPY coumarins, termed COUBPYs. Ru-COUBPY complexes exhibit outstanding in vitro cytotoxicity against CT-26 cancer cells when irradiated with light within the phototherapeutic window, achieving nanomolar potency in both normoxic and hypoxic conditions while remaining nontoxic in the dark, leading to impressive phototoxic indices (>30,000). Their ability to generate both Type I and Type II ROS underpins their exceptional PDT efficiency. The lead compound of this study, SCV49, shows a favorable in vivo pharmacokinetic profile, excellent toxicological tolerability, and potent tumor growth inhibition in mice bearing subcutaneous CT-26 tumors at doses as low as 3 mg/kg upon irradiation with deep-red light (660 nm). These results allow us to propose SCV49 as a strong candidate for further preclinical development, particularly for treating large hypoxic solid tumors., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Ruthenium(II) Polypyridyl Complexes Containing COUBPY Ligands as Potent Photosensitizers for the Efficient Phototherapy of Hypoxic Tumors

  • Abad-Montero, Diego
  • Gandioso, Albert
  • Izquierdo García, Eduardo
  • Chumillas, Sergi
  • Rovira, Anna
  • Bosch, Manel
  • Jordà-Redondo, Mireia
  • Castaño, Davor
  • Bonelli, Joaquín
  • Novikov, Valentin
  • Deyà, Alba
  • Hernández, José Luis
  • Galino, Jorge
  • Alberto, Marta Erminia
  • Francés-Monerris, Antonio
  • Nonell, Santi
  • Gasser, Gilles
  • Marchán, Vicente
Hypoxia, a hallmark of many solid tumors, is linked to increased cancer aggressiveness, metastasis, and resistance to conventional therapies, leading to poor patient outcomes. This challenges the efficiency of photodynamic therapy (PDT), which relies on the generation of cytotoxic reactive oxygen species (ROS) through the irradiation of a photosensitizer (PS), a process partially dependent on oxygen levels. In this work, we introduce a novel family of potent PSs based on ruthenium(II) polypyridyl complexes with 2,2′-bipyridyl ligands derived from COUPY coumarins, termed COUBPYs. Ru-COUBPY complexes exhibit outstanding in vitro cytotoxicity against CT-26 cancer cells when irradiated with light within the phototherapeutic window, achieving nanomolar potency in both normoxic and hypoxic conditions while remaining nontoxic in the dark, leading to impressive phototoxic indices (>30,000). Their ability to generate both Type I and Type II ROS underpins their exceptional PDT efficiency. The lead compound of this study, SCV49, shows a favorable in vivo pharmacokinetic profile, excellent toxicological tolerability, and potent tumor growth inhibition in mice bearing subcutaneous CT-26 tumors at doses as low as 3 mg/kg upon irradiation with deep-red light (660 nm). These results allow us to propose SCV49 as a strong candidate for further preclinical development, particularly for treating large hypoxic solid tumors., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Achieving red-light anticancer photodynamic therapy under hypoxia using Ir(iii)–COUPY conjugates

  • Ortega-Forte, Enrique
  • Rovira, Anna
  • Ashoo, Pezhman
  • Izquierdo García, Eduardo
  • Hally, Cormac
  • Abad-Montero, Diego
  • Jordà-Redondo, Mireia
  • Vigueras Bautista, Gloria
  • Deyà, Alba
  • Hernández, José Luis
  • GALINO, JORGE
  • Bosch, Manel
  • Alberto, Marta Erminia
  • Francés-Monerris, Antonio
  • Nonell, Santi
  • Ruiz, Jose
  • Marchán, Vicente
Despite the potential of photodynamic therapy (PDT), this oxygen-dependent oncological treatment is greatly restricted in the clinic by the well-known hypoxic feature of solid tumors. Here we provide new insights into the development of PDT agents based on conjugates between COUPY fluorophores and cyclometalated iridium(III) complexes with the aim of overcoming this limitation. The structural modifications carried out within the metal core of Ir(III)–COUPY conjugates, based on the incorporation of trifluorobenzyl groups at the cyclometalating ligands, enabled efficient exploitation of type I PDT mechanisms while retaining operativity under long-wavelength visible light, which facilitated deeper tissue penetration compared with short wavelengths. Photobiological evaluation revealed that Ir(III)–COUPY conjugate 3c achieved potent photocytotoxicity towards cisplatin-resistant ovarian (A2780cis) and mammary (EO771) cancer cell lines, efficiently photogenerated type I and type II ROS, and photoinduced apoptotic cell death using red light irradiation (620 nm). Importantly, this Ir(III)–COUPY conjugate retained such potent photoactivity under low-oxygen environment conditions (2% O2), delivering equipotent photocytotoxicity towards normoxic and hypoxic adherent cancer cells. Compound 3c was found to be highly phototoxic against EO771 multicellular tumor spheroids and showed no signs of toxicity or adverse effects in mice, which could facilitate in vivo phototherapeutic applications. Taken together, this study demonstrates that the conjugation between COUPY dyes and rationally designed Ir(III) complexes is a strategy at the frontier of the development of new red light-activated photosensitizers capable of operating under hypoxia, showing the promise of achieving satisfactory anticancer PDT effects., info:eu-repo/semantics/publishedVersion